DEVELOPMENT OF A REVERSED PHASE - HPLC METHOD FOR DETERMINATION OF MELOXICAM IN TABLET FORMULATION AND HUMAN SERUM

Developing a simple, economic, sensitive and rapid isocratic RPHPLC method for determination of meloxicam (MX) in bulk drug, tablet formulation and human serum. The retention time observed for meloxicam was just 2.35 minutes using C18 column (150 x 3.0 mm, 5 μm) with a mobile phase consisting of acetonitrile: 0.2% formic acid (70:30 v/v%) at a flow rate of 1 ml/min with UV detector set at 355 nm. Linearity in concentration range of 0.05 – 50 µg/ml, with coefficient of determination, R² = 0.9956; slope= 25464 and intercept= -8872. The limit of detection and the limit of quantification were found to be 0.011 and 0.173 μg/ml, respectively. The precision and accuracy of method were checked by calculating RSD% and relative error E%, which were found to be reasonable. A RSD% (0.06 and 0.021%) for marketed brand and human serum, respectively and E% (0.64 and -0.47 %) for marketed brand and human serum, respectively. The method was found to be applicable for the analysis of MX in bulk, tablet formulation and human seru

DEVELOPMENT OF A REVERSED PHASE - HPLC METHOD FOR DETERMINATION OF MELOXICAM IN TABLET FORMULATION AND HUMAN SERUM

Developing a simple, economic, sensitive and rapid isocratic RPHPLC method for determination of meloxicam (MX) in bulk drug, tablet formulation and human serum. The retention time observed for meloxicam was just 2.35 minutes using C18 column (150 x 3.0 mm, 5 μm) with a mobile phase consisting of acetonitrile: 0.2% formic acid (70:30 v/v%) at a flow rate of 1 ml/min with UV detector set at 355 nm. Linearity in concentration range of 0.05 – 50 µg/ml, with coefficient of determination, R² = 0.9956; slope= 25464 and intercept= -8872. The limit of detection and the limit of quantification were found to be 0.011 and 0.173 μg/ml, respectively. The precision and accuracy of method were checked by calculating RSD% and relative error E%, which were found to be reasonable. A RSD% (0.06 and 0.021%) for marketed brand and human serum, respectively and E% (0.64 and -0.47 %) for marketed brand and human serum, respectively. The method was found to be applicable for the analysis of MX in bulk, tablet formulation and human seru

Spectrophotometric Method for Determination of Meloxicam in Pharmaceutical Formulations Using N- bromosuccinimide as an Oxidant

Abstract A simple, rapid and sensitive spectrophotometric method has been developed for the determination of meloxicam (MX) in pure form and in its pharmaceutical preparations. The proposed method involve the addition of a measured excess of N-bromosuccinimide (NBS) in acid medium followed by determination of unreacted NBS by reacting with indigo carmine (IC) and measuring the absorbance at 610 nm. The optimum reaction conditions and other analytical parameters have been evaluated. Linearity was observed from 0.2-50 μg/ml meloxicam. Statistical analysis of the results and comparison with results by the British Pharmacopoeia method are also reported. Keywords: Meloxicam, Spectrophotometry, Indigo carmine, N-bromosuccinimide. 1. Introduction Meloxicam, chemically named 4-hydroxy-2-methyl-N (5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide with chemical formula (C 14 H 13 N 3 O 4 S ) and molecular weight 351.4 g/mol ( 2. Experimental 2.1. Apparatus All spectral and absorbance measurements were performed on a (Cecil CE3021-England) UV-VIS spectrophotometer was used for all spectral and absorbance measurements with matched 1 cm quartz cells. Reagents All chemicals were of analytical reagents grade. Stock solution of meloxicam. A stock solution, 500 μg/ml, of the drug under investigation was prepared by dissolving 50 mg (provided by Awamedica Company for Drug Industries and Medical Applications Awa, Erbil, Iraq) in 100 ml of 0.02 M NaOH Shlear H. Hasan et a